Aclara BioSciences Inc., of Mountain View, Calif., appointed John Weinstein to its scientific advisory board.
Adenosine Therapeutics LLC, of Charlottesville, Va., appointed William Gray vice president of licensing and secretary, and Shannon Williams vice president of regulatory affairs and clinical development.
Advanced Viral Research Corp., of Yonkers, N.Y., named Elma Hawkins to its board and as a member of the executive management committee.
Advancis Pharmaceutical Corp., of Germantown, Md., added James Bruno as vice president of sales and Darren Buchwald as vice president of pharmaceutical marketing.
Altea Therapeutics Corp., of Tucker, Ga., appointed David Enscore senior vice president for product research and development.
American Pharmaceutical Partners Inc., of Schaumburg, Ill., appointed Dvorit Samid executive director, medical affairs of Abraxis Oncology, its pharmaceutical division.
Amgen Inc., of Thousand Oaks, Calif., named David Beier senior vice president, global government affairs.
Antisoma plc, of London, appointed Birgit Norinder as nonexecutive director.
Arena Pharmaceuticals Inc., of San Diego, Calif., appointed Donald Belcher, Scott Bice and Robert Toms to its board. It also named Frederick Frank advisory director of its board.
ArQule Inc., Woburn, Mass., appointed Adam Craig vice president, clinical development and medical director, and Louise Mawhinney vice president, finance and chief financial officer.
Avidis SA, of Clermont Ferrand, France, added Brian Morgan, David McNeilly and Thierry Plouvier to its supervisory board.
Cytomedix Inc., of Little Rock, Ark., appointed Charles Baxter chief medical officer and chairman of its medical advisory board.
CytRx Corp., of Los Angeles, added Bruce Spiegelman to the scientific advisory board of its subsidiary, Araios Inc.
DiaDexus Inc., of South San Francisco, appointed David Davidovic vice president of marketing and sales, and Krishna Sudhir vice president, medical affairs.
Discovery Partners International Inc., of San Diego, elected Herm Rosenman to its board, and he also will serve on the audit committee.
Dor BioPharma Inc., of Miami, named Gregory Davenport vice president for business development.
Emisphere Technologies Inc., of Tarrytown, N.Y., appointed Stephen Carter and Michael Black to its board. Joseph Robinson and Jere Goyan resigned their positions and are now consultants to Emisphere.
Enhance Biotech Inc., of New York, appointed Gavin Vinson to its scientific advisory board.
Entelos Inc., of Foster City, Calif., appointed Mikhail Gishizky chief scientific officer.
Gemin X Biotechnologies Inc., of Montreal, appointed Andrew Jordan to its board and to its audit committee.
GeneGo Inc., of St. Joseph, Mich., appointed Charles Cantor to its scientific advisory board.
Genetronics Biomedical Corp., of San Diego, appointed Simon Benito to its board.
Genta Inc., of Berkeley Heights, N.J., appointed Peter Tattle to its board.
Idenix Pharmaceuticals Inc., of Cambridge, Mass., appointed David Arkowitz chief financial officer.
Immtech International Inc., of Vernon Hills, Calif., named Lawrence Potempa chief scientific officer.
Incyte Corp., of Wilmington, Del., appointed Patricia Schreck executive vice president and general counsel.
Interleukin Genetics Inc., of Waltham, Mass., hired Terri Clark as director of clinical affairs, Leon Wilkins as director of functional genetics and John Rogus as director of statistical genetics.
Invitrogen Corp., of Carlsbad, Calif., appointed Cheri Walker vice president, corporate development, and Mark Gardner vice president of process development.
Matritech Inc., of Newton, Mass., elected Patricia Randall as vice president, general counsel and chief legal officer.
Metabolon Inc., of Research Triangle Park, N.C., formed its scientific advisory board, consisting of Hamilton Smith, J. Craig Venter, Paul Schimmel, Oliver Smithies, Flint Beal and Donald Kufe.
Nastech Pharmaceutical Co. Inc., of Bothell, Wash., said Greg Weaver, its chief financial officer, was elected to the board of the Washington Biotechnology & Biomedical Association.
Orexo AB, of Uppsala, Sweden, elected H kan ström, Zsolt Lavotha and Kjell Strandberg to its board.
PamGene International BV, of S Hertogenbosch, the Netherlands, added Bertrand Jordan, Daniel Chan, Herb Heyneker and Peter Lockey to its scientific advisory board.
Parexel International Corp., of Boston, added Matthew Thatcher as principal consultant in the worldwide regulatory affairs group.
Pharsight Corp., of Mountain View, Calif., named Rene Bruno managing director of drug development consulting services for its European operations.
Pro-Pharmaceuticals Inc., of Newton, Mass., added Charles Harney as chief financial officer.
Qualyst Inc., of Research Triangle Park, N.C., formed its scientific advisory board, consisting of Kim Brouwer as chair and Ronald Borchardt, Ken Brouwer, Richard Kim, Anthony Y. H. Lu, Gerald Miwa and Gary Pollack.
Quark Biotech Inc., of Fremont, Calif., appointed Andre Pernet president.
Saegis Pharmaceuticals Inc., of Half Moon Bay, Calif., added Annette Madrid as vice president, clinical.
Sosei Co. Ltd., of Tokyo, appointed Mark Richmond and David Chiswell as nonexecutive directors.
Spectrum Pharmaceuticals Inc., of Irvine, Calif., named Shyam Kumaria vice president of finance.
Stressgen Biotechnologies Corp., of San Diego, named Gregory McKee vice president and chief financial officer.
TargeGen Inc., of San Diego, appointed Ray Gibbons to its scientific advisory board.
Vical Inc., of San Diego, appointed Robert Campbell to its board.
Xencor Inc., of Monrovia, Calif., appointed Bassil Dahiyat chief scientific officer.